23 research outputs found
Clinical and histological characteristics of breast cancer in women with and without hormone replacement therapy (HRT). Results of a national Observatory
Phase ii trial of mitozolomide in patients with advanced ovarian cancer: A study of the eortc gynecological cancer cooperative group
Twenty-seven fully evaluable patients with advanced ovarian cancer and documented disease progression despite cytotoxic treatment were treated with mitozolomide (NCS-353451) 90 mg/m2 as a 1-h infusion once every 6 weeks. None of the patients responded, one had stabilization of disease for 4 months. Haema-tologic toxicity was the major side effect with a nadir or white blood cell counts around day 40. Two patients died with severe leukopenia and septic shock. We conclude that mitozolomide is not active in this poor-risk group of patients. ©1989 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment. Results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at the Netherlands Cancer Institute
Efficacy of Epoetin Alfa in a Retrospective Non-stratified Subgroup Analysis of a Breast Cancer Cohort Receiving Non-platinum Chemotherapy
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
Item does not contain fulltext30 patients with advanced ovarian cancer, all platinum pretreated, were treated with an induction cycle of fotemustine. Maintenance therapy was given to 6 patients. No objective response was observed among the 21 evaluable patients. The main toxicities were gastrointestinal, with grade 3 nausea and vomiting reported in 40% of the patients, and haematological, with grade 4 leucopenia reported in 2 patients and grade 4 thrombocytopenia in 5 patients. Therefore, no role has been demonstrated in our cohort for the use of fotemustine, a nitrosourea, in pretreated ovarian cancer
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract: a phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923)
A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER2-negative, locally recurrent or metastatic breast cancer (LR/MBC)
Choice or necessity? A review of the role of DIY in tackling housing repair and maintenance
Do-it-yourself (DIY) is a staple element of the spare time activities of many households, but little is known about the extent to which basic repair work is carried out through DIY and about the quality of this work. Through secondary analyses of UK government data (English House Condition Survey and Family Expenditure Survey), this paper examines the scale of DIY work by owner-occupiers, how work is organized, the interrelationship of DIY work, the use of unpaid help, and the use of contractors. It considers the types of work carried out, the characteristics of those who tackle DIY or use unpaid help, the dwelling types most likely to experience DIY work, and the motivations of and constraints on those home-owners who do it. The paper concludes with a discussion on the policy implications of these findings for government and the building industry. Although most DIY work is cosmetic and does not deal with basic repair and maintenance, the sheer scale of DIY ensures that it makes a contribution to improving housing conditions. The provision of more advice, information and education by government, local authorities and the private sector could ensure that more DIY work is of better quality and that home owners give priority to essential repairs whether or not they tackle these themselves.Building Do-IT-YOURSELF Housing Maintenance Repair,